Selected Papers from the JSOPB 2021-2022

A special issue of Journal of Clinical Medicine (ISSN 2077-0383). This special issue belongs to the section "Clinical Laboratory Medicine".

Deadline for manuscript submissions: closed (25 October 2022) | Viewed by 11948

Special Issue Editors

Special Issue Information

Dear Colleagues,

This Special Issue is a collection of selected papers from the 47th Japanese Society for Organ Preservation and Biology (JSOPB) (http://jognbio.umin.jp/). The Journal of Clinical Medicine (JCM) is providing an opportunity to publish selected data presented at the annual meeting.

JSOPB was founded in 1974 for the study of organ preservation and developed widely in the 1990s with the participation of researchers in various fields of medicine, pharmacology, engineering, veterinary medicine, and basic science. Currently, the JSOPB has more than 700 members and is run under the direction of Prof. Takashi Kenmochi, the president of the JSOPB.

Excellent presentations conducted at the 47th annual meeting of the JSOPB held 12–13 November 2021, in Tokyo, Japan, under the supervision of Prof. Shohei Fuchinoue (Department of Surgery, Kidney Center, Hidaka Hospital, Gunma, Japan), were selected and given an opportunity to be published in this Special Issue of JCM.

One of the vital missions of the annual meeting of the JSOPB is to exchange new research outcomes and create new therapeutic concepts. Therefore, the aim of the present Special Issue as follows:

  • Molecular and cellular biology of organ preservation and transplantation;
  • Biology of pharmacology;
  • Organ/tissue engineering;
  • Stem cell therapy;
  • Stem cell biology.

Prof. Dr. Hirofumi Noguchi
Prof. Dr. Takashi Kenmochi
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Clinical Medicine is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • Organ preservation
  • Transplantation
  • Pharmacology
  • Engineering
  • Molecular biology
  • Cellular biology
  • Stem cell therapy

Published Papers (5 papers)

Order results
Result details
Select all
Export citation of selected articles as:

Editorial

Jump to: Research, Review

3 pages, 186 KiB  
Editorial
Clinical Islet Transplantation Covered by Health Insurance in Japan
by Hirofumi Noguchi
J. Clin. Med. 2022, 11(14), 3977; https://doi.org/10.3390/jcm11143977 - 08 Jul 2022
Cited by 3 | Viewed by 1091
Abstract
Pancreatic islet transplantation is a treatment option for patients with type 1 diabetes mellitus and has been performed in various countries [...] Full article
(This article belongs to the Special Issue Selected Papers from the JSOPB 2021-2022)

Research

Jump to: Editorial, Review

15 pages, 8241 KiB  
Article
Development of a Cryopreservation Technique for Xenogeneic Kidney Grafts: Evaluation Using a Mouse Model
by Tsuyoshi Takamura, Hiroshi Nagashima, Hitomi Matsunari, Shuichiro Yamanaka, Yatsumu Saito, Yoshitaka Kinoshita, Toshinari Fujimoto, Kei Matsumoto, Kazuaki Nakano, Hirotaka James Okano, Eiji Kobayashi and Takashi Yokoo
J. Clin. Med. 2022, 11(23), 7237; https://doi.org/10.3390/jcm11237237 - 06 Dec 2022
Cited by 1 | Viewed by 1743
Abstract
To align the xeno-metanephros and renal progenitor cell timing for transplantation treatments, cryopreservation techniques and an efficient transportation of regenerated renal products such as xeno-metanephroi and renal progenitor cells should be established. Therefore, we propose a novel method of xenogeneic regenerative medicine for [...] Read more.
To align the xeno-metanephros and renal progenitor cell timing for transplantation treatments, cryopreservation techniques and an efficient transportation of regenerated renal products such as xeno-metanephroi and renal progenitor cells should be established. Therefore, we propose a novel method of xenogeneic regenerative medicine for patients with chronic kidney disease by grafting porcine fetal kidneys injected with human renal progenitor cells. To develop a useful cryopreserve system of porcine fetal kidney and human renal progenitor cells, we examined the cryopreservation of a fetal kidney implanted with renal progenitor cells in a mouse model. First, we developed a new method for direct cell injection under the capsule of the metanephros using gelatin as a support for unzipped fetal kidneys. Then, we confirmed in vitro that the nephrons derived from the transplanted cells were regenerated even after cryopreservation before and after cell transplantation. Furthermore, the cryopreserved chimeric metanephroi grew, and regenerated nephrons were observed in NOD. We confirmed that even in cryopreserved chimeric metanephroi, transplanted cell-derived nephrons as well as fresh transplants grew. Full article
(This article belongs to the Special Issue Selected Papers from the JSOPB 2021-2022)
Show Figures

Figure 1

15 pages, 2669 KiB  
Article
The Role of Genetically Modified Human Feeder Cells in Maintaining the Integrity of Primary Cultured Human Deciduous Dental Pulp Cells
by Natsumi Ibano, Emi Inada, Shinji Otake, Yuki Kiyokawa, Kensuke Sakata, Masahiro Sato, Naoko Kubota, Hirofumi Noguchi, Yoko Iwase, Tomoya Murakami, Tadashi Sawami, Yoshito Kakihara, Takeyasu Maeda, Miho Terunuma, Yutaka Terao and Issei Saitoh
J. Clin. Med. 2022, 11(20), 6087; https://doi.org/10.3390/jcm11206087 - 15 Oct 2022
Cited by 1 | Viewed by 1716
Abstract
Tissue-specific stem cells exist in tissues and organs, such as skin and bone marrow. However, their pluripotency is limited compared to embryonic stem cells. Culturing primary cells on plastic tissue culture dishes can result in the loss of multipotency, because of the inability [...] Read more.
Tissue-specific stem cells exist in tissues and organs, such as skin and bone marrow. However, their pluripotency is limited compared to embryonic stem cells. Culturing primary cells on plastic tissue culture dishes can result in the loss of multipotency, because of the inability of tissue-specific stem cells to survive in feeder-less dishes. Recent findings suggest that culturing primary cells in medium containing feeder cells, particularly genetically modified feeder cells expressing growth factors, may be beneficial for their survival and proliferation. Therefore, the aim of this study was to elucidate the role of genetically modified human feeder cells expressing growth factors in maintaining the integrity of primary cultured human deciduous dental pulp cells. Feeder cells expressing leukemia inhibitory factor, bone morphogenetic protein 4, and basic fibroblast growth factor were successfully engineered, as evidenced by PCR. Co-culturing with mitomycin-C-treated feeder cells enhanced the proliferation of newly isolated human deciduous dental pulp cells, promoted their differentiation into adipocytes and neurons, and maintained their stemness properties. Our findings suggest that genetically modified human feeder cells may be used to maintain the integrity of primary cultured human deciduous dental pulp cells. Full article
(This article belongs to the Special Issue Selected Papers from the JSOPB 2021-2022)
Show Figures

Figure 1

8 pages, 627 KiB  
Article
Functional Outcomes after Selective Clamping in Robot-Assisted Partial Nephrectomy
by Kiyoshi Takahara, Mamoru Kusaka, Takuhisa Nukaya, Masashi Takenaka, Kenji Zennami, Manabu Ichino, Hitomi Sasaki, Makoto Sumitomo and Ryoichi Shiroki
J. Clin. Med. 2022, 11(19), 5648; https://doi.org/10.3390/jcm11195648 - 25 Sep 2022
Cited by 2 | Viewed by 1183
Abstract
This study aimed to assess the risks and benefits of selective clamping in robot-assisted partial nephrectomy (RAPN). We retrospectively analyzed 372 patients who had undergone RAPN at our hospital between July 2010 and March 2021. After propensity score matching between the full and [...] Read more.
This study aimed to assess the risks and benefits of selective clamping in robot-assisted partial nephrectomy (RAPN). We retrospectively analyzed 372 patients who had undergone RAPN at our hospital between July 2010 and March 2021. After propensity score matching between the full and selective clamping groups, perioperative outcomes and postoperative preservation ratio of the estimated glomerular filtration rate (eGFR) were compared at 6 and 12 months of follow-up. After propensity score matching, we evaluated 47 patients from each group. While no significant differences were observed in surgical time, warm ischemia time, or incidence rates of all grades of complications between the two cohorts, the estimated blood loss (EBL) was significantly lower in the full clamping group than in the selective clamping group (30 vs. 60, p = 0.046). However, no significant intergroup differences were observed in the postoperative preservation ratio of eGFR at 6 or 12 months of follow-up (full clamping 94.0% vs. selective clamping 92.7%, p = 0.509, and full clamping 92.0% vs. selective clamping 91.6%, p = 0.476, respectively). Selective clamping resulted in higher EBL rates than did full clamping in RAPN. However, selective clamping provided no renal functional advantage over full clamping in our propensity-score-matched cohort. Full article
(This article belongs to the Special Issue Selected Papers from the JSOPB 2021-2022)
Show Figures

Figure 1

Review

Jump to: Editorial, Research

16 pages, 276 KiB  
Review
Clinical Trials of Stem Cell Therapy in Japan: The Decade of Progress under the National Program
by Shin Enosawa
J. Clin. Med. 2022, 11(23), 7030; https://doi.org/10.3390/jcm11237030 - 28 Nov 2022
Cited by 2 | Viewed by 5027
Abstract
Stem cell therapy is a current world-wide topic in medical science. Various therapies have been approved based on their effectiveness and put into practical use. In Japan, research and development-related stem cell therapy, generally referred to as regenerative medicine, has been led by [...] Read more.
Stem cell therapy is a current world-wide topic in medical science. Various therapies have been approved based on their effectiveness and put into practical use. In Japan, research and development-related stem cell therapy, generally referred to as regenerative medicine, has been led by the government. The national scheme started in 2002, and support for the transition to clinical trials has been accelerating since 2011. Of the initial 18 projects that were accepted in the budget for preclinical research, 15 projects have begun clinical trials so far. These include the transplantation of retinal, cardiac, and dopamine-producing cells differentiated from human induced pluripotent stem (iPS) cells and hepatocyte-like cells differentiated from human embryonic stem (ES) cells. The distinctive feature of the stem cell research in Japan is the use of iPS cells. A national framework was also been set-up to attain the final goal: health insurance coverage. Now, insurance covers cell transplantation therapies for the repair and recovery of damaged skin, articular cartilage, and stroke as well as therapies introduced from abroad, such as allogeneic mesenchymal stem cells for graft-versus-host disease and chimeric antigen receptor-T (CAR-T) cell therapy. To prepare this review, original information was sought from Japanese authentic websites, which are reliable but a little hard to access due to the fact of multiple less-organized databases and the language barrier. Then, each fact was corroborated by citing its English version or publication in international journals as much as possible. This review provides a summary of progress over the past decade under the national program and a state-of-the-art factual view of research activities, government policy, and regulation in Japan for the realization of stem cell therapy. Full article
(This article belongs to the Special Issue Selected Papers from the JSOPB 2021-2022)
Back to TopTop